Drug intelligence / Profile preview

fish oil triglycerides

Development stage
Approved
Lead developer
Fresenius Kabi
Modality
Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

**Fish oil triglycerides** is a sterile intravenous lipid emulsion marketed as **Omegaven** by Fresenius Kabi. It is a fish oil-based source of calories and essential fatty acids containing long-chain omega-3 polyunsaturated fatty acids, principally eicosapentaenoic acid and docosahexaenoic acid. The product is approved in the United States for pediatric parenteral nutrition-associated cholestasis. In the completed Aalborg University Hospital Phase 2 hemodialysis study, a high-n-3 fatty-acid lipid emulsion was evaluated for acute effects on heart-rate variability, ventricular repolarization, and ventricular arrhythmias as markers of sudden cardiac-death risk. The proposed antiarrhythmic mechanism is rapid elevation of circulating free omega-3 fatty acids, which may alter myocardial membrane electrical stability rather than act through one defined drug receptor. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210589s005lbl.pdf))

Brand names
Omegaven
Other names
Omegaven 10%omega-3 fish oil lipid emulsionomega3 fish oil lipid emulsionomega 3 fish oil lipid emulsionhigh n-3 polyunsaturated fatty acid lipid emulsion
02

Targets

Hepatic very-low-density lipoprotein (VLDL) synthesis and secretion machineryCACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on fish oil triglycerides.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fish oil triglycerides.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call